Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • December 27, 2018 8:52 AM | Anonymous

    December 27, 2018, SELF 
    via Center for Healthy Women & Children, National Coalition for Sexual Health  

    Trying to understand health insurance can be like learning a foreign language that might cost you a boatload of money if anything gets lost in translation. But here’s one clear health insurance fact: The Affordable Care Act allows young adults to stay on a parent or guardian’s job- or marketplace-provided insurance until they are 26. This is excellent.

    Read more.

  • December 27, 2018 8:43 AM | Anonymous

    December 27, 2018, MedPage Today  

    Women's risk of breast cancer was highest about 5 years after childbirth, and lasted more than 20 years, compared with women who have never given birth, and breastfeeding did not appear to attenuate the risk, a large pooled analysis found. 

    Read more.

  • December 21, 2018 8:33 AM | Anonymous

    December 21, 2018, MedPage Today  

    Use of vaginal estrogen wasn't tied to increased cardiovascular or cancer risks, according to a new study.

    Looking at postmenopausal women who participated in the Nurses' Health Study, vaginal estrogen use in women with or without an intact uterus was not associated with any increased risks of several cancers or cardiovascular outcomes over an 18-year follow-up period, reported JoAnn E. Manson, MD, DrPH, of Brigham and Women's Hospital in Boston, and colleagues.

    Read more.

  • December 20, 2018 8:18 AM | Anonymous

    December 20, 2018, News Medical 

    Researchers at the Queen Mary University of London have developed a new cervical cancer test that proved to be 100 percent effective at detecting the cancer in a trial of 15,744 participants. The study demonstrated that the epigenetics-based test outperformed both the Pap smear and the human papilloma virus (HPV) test, as well as being more cost effective. 

    Read more.

  • December 19, 2018 9:29 AM | Anonymous

    December 19, 2018, MedPage Today  

    Women up to age 40 who have residual tumor in either the breast or lymph nodes following neoadjuvant chemotherapy had higher rates of recurrence compared with women with no residual invasive tumor, according to a retrospective study. 

    Read more. 

  • December 19, 2018 9:25 AM | Anonymous

    December 19, 2018, MedPage Today 

    The risk of pelvic floor disorders for women years after childbirth varied depending on mode of delivery, researchers found.Women with cesarean delivery had a lower hazard of stress urinary incontinence, overactive bladder, and pelvic organ prolapses compared with women with spontaneous vaginal deliveries, reported Joan L. Blomquist, MD, of Greater Baltimore Medical Center in Maryland, and colleagues.

    Read more.
  • December 18, 2018 11:24 AM | Anonymous

    December 18, 2018, HealthDay News  

    For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in terms of reduced toxicity and results in worse tumor control, according to a study recently published in The Lancet. 

    Read more. 

  • December 18, 2018 11:22 AM | Anonymous

    December 18, 2018, Medscape 

    Nearly half of patients with breast cancer who, on multigene panel testing, are found to have a pathogenic or likely pathogenic variant for breast cancer do not meet current National Comprehensive Cancer Network (NCCN) guidelines for genetic testing, new research shows.  

    Read more.

  • December 12, 2018 3:05 PM | Anonymous

    December 12, 2018, MedPage Today 

    The frequency of cardiotoxicity declined significantly with prophylactic antihypertensive medication for patients with early HER2-positive breast cancer treated with anthracycline-containing chemotherapy, but not trastuzumab (Herceptin), a randomized trial showed. 

    Read more.

  • December 12, 2018 3:03 PM | Anonymous

    December 12, 2018, MedPage Today  

    Extending adjuvant endocrine therapy with an aromatase inhibitor to 10 years led to significant improvement in disease-free survival (DFS) and distant (DDFS) in postmenopausal women with hormone receptor-positive (HR-positive) breast cancer, Japanese investigators reported. 

    Read more.


Powered by Wild Apricot Membership Software